Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

June 03, 2022

The selective EGFR inhibitor CLN-081 elicited objective responses in heavily pretreated patients with non–small cell lung cancer with EGFR exon 20 insertions and was found to have an acceptable toxicity profile, according to data from the phase 1/2a CLN-081-001 trial.

June 02, 2022

The combination of the humanized anti-GD2 antibody naxitamab-gqgk, irinotecan, temozolomide, and sargramostim met its primary end point for objective response rate in patients with chemoresistant high-risk neuroblastoma.

June 01, 2022

Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.

May 18, 2022

Selinexor monotherapy prolonged progression-free survival, time to next treatment, and reduced pain in patients with advanced, refractory dedifferentiated liposarcoma.

May 17, 2022

The American Urologic Association in collaboration with the American Society for Radiation Oncology has issued new practice guidelines for the management of clinically localized prostate cancer.

May 11, 2022

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

May 03, 2022

Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.

April 28, 2022

Steven Maron, MD, MSc, discusses sequencing considerations in the frontline treatment of gastrointestinal cancers.

April 14, 2022

Steven Maron, MD, MSc, discusses HER2-positive tumors in esophageal gastric cancers.

April 07, 2022

Checkpoint inhibitors prior to allogeneic hematopoietic cell transplant improved progression-free survival and relapse incidence in patients with Hodgkin lymphoma, but the treatment did not improve non-relapse mortality or overall survival.

April 04, 2022

“I can’t conceive of anything worse than being in a situation where you can’t ask, ‘How do we get better?’ ”

March 30, 2022

Eytan M. Stein, MD, discusses the key highlights of the phase 1/2 AUGMENT-101 trial in leukemias.

March 21, 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.

March 21, 2022

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

March 21, 2022

Miguel-Angel Perales, MD, discusses the science behind Orca-T and other approaches targeted to improve GVHD relapse-free survival in select patients with hematologic cancers.

March 16, 2022

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

March 13, 2022

The historical boundaries of what was possible in the management of patients with breast cancer continue to be challenged, evidenced by the use of HER2-directed therapies in patients with brain metastases, de-escalated approaches in patients with visceral disease, and less-invasive surgical techniques for patients with lymph node involvement.

March 11, 2022

Tiffany Traina, MD, discusses the body of evidence supporting the use of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, shifting standards of care in HER2-positive disease, as well as biomarkers of response with checkpoint inhibitors and PARP inhibitors in triple-negative breast cancer.

March 10, 2022

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

March 08, 2022

Although the addition of copanlisib to ibrutinib resulted in a high overall response rate in patients with relapsed/refractory mantle cell lymphoma, the regimen was found to have additive toxicity, according to findings from a small phase 1 trial.